With Takeda still eyeing a buy, Shire casts off oncology drugs for $2.4B
admin 16th April 2018 Uncategorised 0With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own. Monday, Shire said it had agreed to hand its oncology business to France’s Servier for $2.4 billion, a move the company said would sharpen its focus on rare diseases.
More: With Takeda still eyeing a buy, Shire casts off oncology drugs for .4B
Source: fierce